Pharmaceuticals
Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients
SUZHOU, China, Jan. 10, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr.Andy Goren and Dr. Flávio Adsuara C...
2021-01-10 16:55
3799
NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis
MILAN and HONG KONG, Jan. 8, 2021 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agr...
2021-01-08 20:55
6076
Atsushi Sugita Succeeds Koichi Takagi as President & CEO of Maruho
OSAKA, Japan, Jan. 8, 2021 /PRNewswire/ -- Maruho Co., Ltd. (hereinafter "Maruho"), based inOsaka, Japan, announced that its Board of Directors has named Atsushi Sugita Representative Director, President & CEO, effective December 18, 2020. Koichi Takagi has served as President & CEO since 1999 and...
2021-01-08 14:00
4912
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
- Ocular Pain, a $10+ billion global market, with significant unmet medical need - License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies IRVINE, California, PARIS, HONG KONG, Jan. 7, 2021 /PRNewswire/ -- IACTA Pharmaceuticals, Inc...
2021-01-07 20:00
2572
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 can be a safe, tolerable and efficacious adjunct to current ...
2021-01-06 21:00
4514
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-01-06 20:24
6341
Yiling Pharma expects to double its YoY net profit in 2020
SHIJIAZHUANG, China, Jan. 6, 2021 /PRNewswire/ -- Yiling Pharmaceutical, a Shenzhen stock market listed enterprise (002603.SZ), has recently published its 2020 earnings projection. The yearly net profit belonging to its shareholders is anticipated to be between 1.152 billion Chinese yuan and 1.27...
2021-01-06 16:55
7251
Connect Biopharma Establishes Scientific Advisory Board Comprised of Clinical Development and Program Indication Experts
Company's product development strategies to be enhanced by deep experience in dermatology, allergy and inflammatory diseases and successful drug approvals SAN DIEGO and TAICANG, SUZHOU, China, Jan. 5, 2021 /PRNewswire/ -- Connect Biopharma, a global clinical-stage biopharmaceutical company focuse...
2021-01-05 21:00
2425
Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"
SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III cl...
2021-01-05 17:49
3005
Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer
SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-05 08:00
3873
AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy(TM)
SEATTLE, Jan. 4, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics' Libmeldy™, which was recently approved by the European Commission (EC) as a one-time therapy for ...
2021-01-04 22:30
4059
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("A...
2021-01-04 21:00
5188
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-04 08:00
4575
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of ...
2020-12-31 22:38
8773
WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries
STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory coveri...
2020-12-31 09:00
5310
Modern Chinese Medicine Group Co., Ltd. to raise a maximum of approximately HK$221 million by way of Public Offer and Placing
Highlights * The Group principally engages in the production of proprietary Chinese medicine (the "PCM") in particular, and the Group offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. * During the Track Record Period and up to 21 Decembe...
2020-12-30 23:38
15510
Insilico enters into a collaboration with APRINOIA to apply novel generative AI-powered system to discover novel compounds for neurodegenerative diseases
TAIPEI, Taiwan, Dec. 30, 2020 /PRNewswire/ -- Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compou...
2020-12-30 10:29
4603
WuXi Biologics Receives GMP Certification from Brazil's ANVISA
* First company in China to receive GMP certification for the production of biologics from the U.S. FDA, EMA and ANVISA WUXI, China, Dec. 28, 2020 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that ...
2020-12-28 17:50
3447
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial
SHANGHAI, Dec. 28, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announces today dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor (F...
2020-12-28 08:30
4381
Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma
SAN FRANCISCO and SUZHOU, China, Dec. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2020-12-28 08:00
8971
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
